Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration | Zendy

Judith Leitner | Zendy; B Meyer | Zendy; Valentin Fuhrmann | Zendy; K. Saria | Zendy; C. Zuba | Zendy; Walter Jäger | Zendy; Michaela Böhmdorfer | Zendy; Florian Thalhammer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration

Author(s) -

Judith Leitner,

B Meyer,

Valentin Fuhrmann,

K. Saria,

C. Zuba,

Walter Jäger,

Michaela Böhmdorfer,

Florian Thalhammer

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq545

Subject(s) - anidulafungin , pharmacokinetics , medicine , volume of distribution , renal replacement therapy , dosing , population , renal function , pharmacology , urology , antifungal , fluconazole , caspofungin , environmental health , dermatology

Clinical studies support a role for anidulafungin as first-line treatment of invasive candidiasis in critically ill patients and postulate no need for dose adjustments in mild to severe renal failure. Although intensive care patients requiring renal replacement therapy are at particular risk of invasive fungal infection, no pharmacokinetic data on anidulafungin during continuous venovenous haemoltration (CVVHF) are available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research